Results 131 to 140 of about 647,233 (310)

SPG4 and Dementia: Expanding the Clinical Spectrum

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Hereditary spastic paraplegia (HSP) is a group of disorders characterized by progressive spasticity and lower limb weakness, with mutations in SPG4/SPAST being the most common cause. Detailed studies and clinical and molecular comparisons across different populations are missing.
Emanuele Panza, Arun Meyyazhagan, Eliseo Picchi, Gustavo Ribas, Ingrid Faber, Ryosuke Miyamoto, Preethi Basavaraju, Paolo Eusebi, Haripriya Kuchi Bhotla, Mario Stasi, Fabrizio Gaudiello, Francesco Patti, Filippo Maria Santorelli, Marcondes Cavalcante França Jr, José Luiz Pedroso, Orlando Graziani Povoas Barsottini, Hélio Afonso Ghizoni Teive, Peter Henry St George‐Hyslop, Toshitaka Kawarai, Antonio Orlacchio   +19 more
wiley   +1 more source

Predeath Grief, Resourcefulness, and Perceived Stress Among Caregivers of Partners With Young-Onset Dementia [PDF]

, 2019
More than 200,000 Americans are currently diagnosed with young-onset dementia (YOD). YOD is dementia diagnosed prior to the age of 65. Most persons of YOD are cared for by their partners.
Bekhet, Abir K., Frenn, Marilyn, Garnier-Villarreal, Mauricio, Kobiske, Karie Ruekert   +3 more
core   +1 more source

Additional file 1: of Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimerâ s disease

, 2019
Table S1. Participantsâ family mutations. (DOCX 17 kb)
Weston, Philip, Poole, Teresa, O’Connor, Antoinette, Heslegrave, Amanda, Ryan, Natalie, Liang, Yuying, Druyeh, Ronald, Mead, Simon, Blennow, Kaj, Schott, Jonathan, Frost, Chris, Zetterberg, Henrik, Fox, Nick   +12 more
openaire   +1 more source

ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration. Glycolytic dysregulation is implicated in disease progression, yet the underlying mechanisms remain unclear. This study investigates how Aldolase A (ALDOA) drives ALS progression through glycolysis‐mediated motor neuron pyroptosis.
Kaixin Yan, Yan Jiang, Yuxuan Yong, Tianshuo Zhang, Niannian Zhang, Qianqian Zeng, Xue Gong, Li Meng, Fangfang Bi, Yongmin Liu   +9 more
wiley   +1 more source

Additional file 1: of Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimerâ s disease

, 2017
Cost-effectiveness of cerebrospinal biomarkers for Alzheimerâ s diagnosis: supplemental Methods, Results, figures and tables as referenced in the text. (DOCX 91 kb)
Lee, Spencer, Sposato, Luciano, Hachinski, Vladimir, Cipriano, Lauren   +3 more
openaire   +1 more source

Nutraceuticals in cognitive impairment and Alzheimer’s disease

Frontiers in Pharmacology, 2014
Several chemical substances belonging to classes of natural dietary origin display protective properties against some age-related diseases including neurodegenerative ones, particularly Alzheimer's disease (AD). These compounds, known as nutraceuticals, differ structurally, act therefore at different biochemical and metabolic levels and have shown ...
Mecocci, P., Tinarelli, C., Schulz, R. J., Polidori, M. C.   +3 more
openaire   +3 more sources

[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, Gérard N. Bischof, Robert Perneczky, Boris‐Stephan Rauchmann, Simon Lindner, Günter U. Höglinger, Rudolf A. Werner, Martin Kerschensteiner, Tania Kümpfel, Matthias Brendel, Franziska S. Thaler   +19 more
wiley   +1 more source

Additional file 7: of Beneficial effects of curtailing immune susceptibility in an Alzheimerâ s disease model

, 2019
Figure S7. Negative controls for Fig. 8, panel b (phosphorylated Tau protein expression). Negative controls are reported in all panels marked with acronyms of secondary antibodies labeled with, Alexa Fluor 488. (PDF 491 kb)
Benedetto, Giulia Di, Burgaletto, Chiara, Carta, Anna, Saccone, Salvatore, Lempereur, Laurence, Mulas, Giovanna, Loreto, Carla, Bernardini, Renato, Cantarella, Giuseppina   +8 more
openaire   +1 more source

Longitudinal Assessment of Biomarkers in ALS: Discriminative Biomarkers for Disease Progression and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers, Yueh‐Yun Lin, Jason R. Thonhoff, Aaron D. Thome, Alireza Faridar, Weihua Zhao, Shixiang Wen, Stanley H. Appel   +7 more
wiley   +1 more source

PND99 A STUDY OF PREFERENCES FOR DISEASE-MODIFYING TREATMENTS FOR ALZHEIMER’S DISEASE

Value in Health, 2020
C. Poulos, B. Hauber, F. Mirzaei, A. Dilley, C. DeMuro, H.M. Fillit   +5 more
openaire   +1 more source